ArticleJACC. Case reports2025
Severe Late-Onset Anthracycline-Induced Cardiotoxicity in Breast Cancer Survivor Patient: Importance of Post-Chemotherapy Surveillance.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cardioprotective SNPs in SLC28A3 and lncRNA SLC28A3-AS1 result in transcriptional changes and alternative splicing to reduce doxorubicin cytotoxicity.Human molecular genetics · 2026Article
- Chemo-/radiotherapy-induced cardiomyopathy: roles of mitochondria and endoplasmic reticulum.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeft ventricular (LV) dysfunction is a common and serious complication from cancer treatment. One of the common regimens that can cause cardiotoxicity is anthracycline, and anthracycline-induced cardiotoxicity may manifest after several years. CASE SUMMARY: A 32-year-old woman presented with heart failure syndrome late after chemotherapy administration for breast cancer therapy. Several months after chemotherapy completion, patient presented with overt LV dysfunction. The guideline-directed medical treatment was initiated. Patient demonstrated gradual recovery and progressive improvement of myocardial systolic performance with LV thrombus resolution after 5-month evaluation. DISCUSSION: The recognition of cancer therapy-related cardiac dysfunction (CTRCD) is important since early detection and treatment with heart failure treatment provide a good functional recovery and long-term prognosis. The clinical application of longitudinal strain and myocardial work echocardiography in CTRCD cases for therapeutic response tracking and prognostication purposes is recommended. TAKE-HOME MESSAGE: Long-term postchemotherapy echocardiography evaluation especially in high-risk CTRCD criteria is of utmost importance due to the possibility of late-onset CTRCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.